In AML, an OR gate TCE approach would be predicted to be challenging, since the once-robust industry pipeline of TCEs against single AML TAAs (CD123, CD33, CLL1, WT1 pMHC) has been nearly entirely discontinued (46), in large part due to high grade CRS and other adverse events at doses that produces unremarkable overall response rates (47–49). This evidence concerns the gene CD33 and acute myeloid leukemia.